Bargain hunters swooped in on Catalent stock after it entered oversold territory. Catalent’s end-market demand appears to be deteriorating. The disappointing start to the year led management to backpedal on its outlook. The company still has valuable partnerships with leading drug makers and consumer health companies. Last fall, Catalent, Inc. (NYSE:CTLT) climbed to a record […]